Geneva – U.S. drugmaker Merck & Co. announced a deal Wednesday that could see generic versions of its COVID-19 medication widely distributed in poorer countries, in a first during the pandemic.
The global Medicines Patent Pool (MPP) said it had signed a voluntary licensing agreement with Merck to facilitate affordable worldwide access to molnupiravir, the company’s investigational oral antiviral medicine.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.